Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62,162,717
-
Total 13F shares
-
59,706,248
-
Share change
-
+1,618,552
-
Total reported value
-
$1,727,301,180
-
Put/Call ratio
-
203%
-
Price per share
-
$28.93
-
Number of holders
-
182
-
Value change
-
+$61,111,527
-
Number of buys
-
108
-
Number of sells
-
73
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q1 2024
As of 31 Mar 2024,
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) was held by
182 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
59,706,248 shares.
The largest 10 holders included
FARALLON CAPITAL MANAGEMENT LLC, BlackRock Inc., RTW INVESTMENTS, LP, BVF INC/IL, STATE STREET CORP, VANGUARD GROUP INC, JOHNSON & JOHNSON, ADAGE CAPITAL PARTNERS GP, L.L.C., MORGAN STANLEY, and COWEN AND COMPANY, LLC.
This page lists
182
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.